1. Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R, Alam MT, Li C, Annan DA, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, *Hida K: Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system, Cancer Sci., in press
2. Nishiyama K, Takahashi K, Fukuyama M, Kasuya M, Imai A, Usukura T, Maishi N, Maeki M, Ishida A, Tani H, Hida K, Shigemura K, Hibara A, Tokeshi M: Facile and rapid detection of SARS-CoV-2 antibody based on a noncompetitive fluorescence polarization immunoassay in human serum samples, Biosens. Bioelectron., 2021,190:113414. doi: 10.1016/j.bios.2021.113414
3. Torii C§, Maishi N§, Kawamoto T§, Morimoto M, Akiyama K, Yoshioka Y, Minami T, Tsumita T, Alam MT, Ochiya T, Hida Y, *Hida K: miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells, Sci Rep, 2021, 11:13502 doi.org/10.1038/s41598-021-92879-5
4. Cong Li, Maishi N, Annan DA, Young MF, Morimoto H, Morimoto M, Nam JM, Hida Y, *Hida K: Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy, Breast Cancer Res., 2021, 23:51 doi.org/10.1186/s13058-021-01423-w
5. Yanagiya M, Dawood RIH, Maishi N, Hida Y, Torii C, Annan DA, Kikuchi H, Yanagawa Matsuda A, Kitamura T, Tei K, Shindoh M, Tanaka S, Kitagawa Y, *Hida K: Correlation between endothelial chemokine receptor 7CXCR7 expression and clinicopathological factors in oral squamous cell carcinoma, Pathol. Int., 2021:71:383-391. doi: 10.1111/pin.13094
6. Morimoto H, Hida Y, Maishi N, Nishihara H, Hatanaka Y, Li C, Matsuno Y, Nakamura T, Hirano S, *Hida K: Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer, Thorac. Cancer, 2021, 12(9), 1347-1357 doi:10.1111/1759-7714.13907